Atlas Trials

Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

Clinical trial NCT06650332 · RECRUITING

Trial details

NCT number
NCT06650332
Sponsor
Zhejiang Cancer Hospital
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Metastatic HER2 Positive Gastroesophageal Junction Cancer
Start date
2024-07-10
Primary completion
2026-08-10
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.